Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
10,107
datasets available to search
ShareScore release 0.9.0
Dataset results
10,107 results for “chemotherapy”
Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
ClinicalTrials.gov study NCT03273426. IPD Sharing: YES. Countries: 1. Publications: 1.
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
ClinicalTrials.gov study NCT03314935. IPD Sharing: YES. Countries: 3. Publications: 1.
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
ClinicalTrials.gov study NCT04390763. IPD Sharing: YES. Countries: 14. Publications: 0.
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCL
ClinicalTrials.gov study NCT03631199. IPD Sharing: YES. Countries: 41. Publications: 1.
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT03512197. IPD Sharing: YES. Countries: 20. Publications: 0.
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
ClinicalTrials.gov study NCT04266795. IPD Sharing: YES. Countries: 5. Publications: 1.
Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
ClinicalTrials.gov study NCT01515748. IPD Sharing: YES. Countries: 1. Publications: 2.
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
ClinicalTrials.gov study NCT02039726. IPD Sharing: YES. Countries: 19. Publications: 3.
Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC
Open the record for dataset details and reuse information.
Data from: Chemotherapy Modulation by a Cancer-Associated Microbiota Metabolite
<p>Data from the manuscript: </p> <p><strong>Chemotherapy Modulation by a Cancer-Associated Microbiota Metabolite</strong></p> <p><em>Summary - </em><em>Revealed once accepted</em></p> <p>The data in this repository covers the following datasets:</p> <ul> <li>4-way screening of BW, pyrE and the triple mutant (TM) -> <em>4_way.csv </em>files</li> <li>RNA-seq raw and normalised counts (from salmon), with their metadata -> files starting with <em>RNAseq</em></li> <li>Proteomics data from Perseus</li> <li>Biolog metabolites for PM plates PM-PM11 to PM14 with a curated classification of their targets, molecule types and processes -><em> biolog_metabolites_cancer.xlsx</em></li> <li>Drug (Biolog and DrugBank) fingerprints -> <em>Drug_FP.xlsx</em></li> </ul>
Heterogeneity of RNA editing in mesothelioma and how RNA editing enzyme ADAR2 affects mesothelioma cell growth, response to chemotherapy and tumor microenvironment
<p>Raw data supporting the manuscript</p>
Monitoring of neoadjuvant chemotherapy through time domain diffuse optics: Breast tissue composition changes and collagen discriminative potential
<p>This dataset serves as a comprehensive resource containing the raw data, analyses, and various tools utilized to produce the findings that are presented in our paper titled ‘<strong>Monitoring of neoadjuvant chemotherapy through time domain diffuse optics: breast tissue composition changes and collagen discriminative potential</strong>’. </p> <p>The aim of this clinical study is to test broad spectral range (635-1060 nm) time domain diffuse optical spectroscopy to monitor the response of breast cancer patients to neoadjuvant chemotherapy. Preliminary results from patients on changes in hemoglobin, water, lipids, collagen concentrations, and scattering parameters due to the therapy are presented. In these initial results, we hypothesize that collagen could be a possible biomarker to distinguish complete and partial responders.</p>
Dataset related to article "Tumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells"
<p>This record contains data related to article “Tumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells”</p> <p><span>Tumor Treating Fields (TTFields) applied with standard chemotherapy have been approved for the first-line treatment of unresectable pleural mesothelioma (PM), an aggressive malignancy with limited effective therapy options.</span></p> <p><span>In this study, we demonstrated that the simultaneous exposure to TTFields and doxorubicin or vinorelbine enhanced treatment efficacy in patient-derived PM cells by increasing intracellular drug concentrations. This was achieved by modulating several genes that encode transport proteins, such as the downregulation of P-glycoprotein.</span></p> <p><span>Using specific, sensitive and quantitative analytical techniques, we observed a more than 70% increase in intracellular concentrations of doxorubicin and vinorelbine in samples treated with TTFields, and a greater than 50% increase in drug uptake in cells exposed to TTFields and pemetrexed. This result indicates that the increased drug concentration observed in TTFields treated cells is significant not only for drugs that are P-gp substrates but also suggests that TTFields could potentially affect other efflux pumps. However, the co-exposure to the drug and TTFields was critical to increasing intracellular drug levels, highlighting the necessity of concurrent use with drugs to enhance the antiproliferative effects of treatment.</span></p> <p><span>The <em>in vitro</em> findings were further corroborated by <em>in vivo</em> pharmacokinetic experiments in mice subcutaneously injected with epithelioid PM tumors. Indeed, a 30% increase in intratumor concentrations was observed when vinorelbine was administered with TTFields.</span></p> <p><span>Our findings suggest that TTFields could be a well-tolerated approach for enhancing intratumoral drug levels and potentially achieving a more significant therapeutic impact on PM treatment.</span></p>
Database on chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer - results from the observational CICARO Study
<p>Raw data and edited data on the observational CICARO-study on chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer</p>
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
ClinicalTrials.gov study NCT03184870. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
ClinicalTrials.gov study NCT04134429. IPD Sharing: YES. Countries: 1. Publications: 1.
Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
ClinicalTrials.gov study NCT04406857. IPD Sharing: YES. Countries: 1. Publications: 1.
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
ClinicalTrials.gov study NCT04068610. IPD Sharing: YES. Countries: 5. Publications: 1.
High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
ClinicalTrials.gov study NCT02416206. IPD Sharing: Not stated. Countries: 1. Publications: 26.
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT00265850. IPD Sharing: Not stated. Countries: 2. Publications: 8.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.